Michael A. Papagikos
Expertise in
36
conditions

Dr. Michael A. Papagikos

Radiation Oncology
1988 S 16th St, 
Wilmington, NC 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
36
conditions
1988 S 16th St, 
Wilmington, NC 

Overview

Michael Papagikos is a Radiation Oncologist practicing medicine in Wilmington, North Carolina.

Dr. Papagikos is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

Dr. Papagikos is board certified in Radiation Oncology. He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 11 clinical trials. Dr. Papagikos is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in NC

Board Certifications

Radiation Oncology

Hospital Affiliations

Novant Health New Hanover Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Coastal Carolina Radiation Oncology - Wilmington
1988 S 16th St, Wilmington, NC 28401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 9 Less Clinical Trials

7 Total Publications

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 14, 2023
Similar Doctors
Expertise in
37
conditions
Dr. Michael A. Nichols
Radiation Oncology
Expertise in
37
conditions
Dr. Michael A. Nichols
Radiation Oncology
Referral may be required
Before you request

Coastal Carolina Radiation Oncology - Wilmington

1988 S 16th St, 
Wilmington, NC 
 (0.1 miles away)
910-662-8440
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Nichols is a Radiation Oncologist practicing medicine in Wilmington, North Carolina. Dr. Nichols is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Small Cell Lung Cancer (SCLC). Dr. Nichols is board certified in Radiation Oncology. Dr. Nichols is currently accepting new patients.

Expertise in
50
conditions
Dr. Patrick D. Maguire
Radiation Oncology
Expertise in
50
conditions
Dr. Patrick D. Maguire
Radiation Oncology
Referral may be required

Coastal Carolina Radiation Oncology PLLC

1988 S 16th St, 
Wilmington, NC 
 (0.1 miles away)
910-251-1839
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Maguire is a Radiation Oncologist practicing medicine in Wilmington, North Carolina. Dr. Maguire is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Posterior Fossa Tumor. Dr. Maguire is currently accepting new patients.

Expertise in
39
conditions
Dr. Tiffany M. Morgan
Radiation Oncology
Expertise in
39
conditions
Dr. Tiffany M. Morgan
Radiation Oncology
Referral may be required
Before you request

Coastal Carolina Radiation Oncology - Wilmington A

1988 S 16th St, Ste A, 
Wilmington, NC 
 (0.1 miles away)
910-662-8440
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tiffany Morgan is a Radiation Oncologist practicing medicine in Wilmington, North Carolina. Dr. Morgan is highly rated in 39 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Posterior Fossa Tumor. Dr. Morgan is board certified in Radiation Oncology. Dr. Morgan is currently accepting new patients.

Frequently Asked Questions about Dr. Michael A. Papagikos

How do I make an appointment with Dr. Michael A. Papagikos?

You can book an appointment with Dr. Michael A. Papagikos by calling their office at 910-662-8440. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Papagikos a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Papagikos is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Papagikos specialize in?

While Dr. Michael A. Papagikos is a Radiation Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Michael A. Papagikos participate in research or clinical trials?

Yes. Dr. Michael A. Papagikos has published 7 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Michael A. Papagikos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Papagikos accept my insurance?

Dr. Michael A. Papagikos accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 910-662-8440 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papagikos's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile